面对传统CRISPR基因筛选在体内模型中的瓶颈效应和数据噪声问题，研究人员开发出了这种创新技术——CRISPR-StAR（Stochastic Activation by ...

自 2012 年 CRISPR-Cas9 基因编辑技术问世以来 ... CRISPRMax Cas9基因编辑方式 1. 通过共转染Cas9 mRNA与sgRNA，成功表达Cas9蛋白。 2. Cas9蛋白与sgRNA在细胞内 ...

大家都知道，CRISPR/Cas9基因编辑技术在高效获得基因敲除突变（knockout）方面是非常有效的，但是想要通过同源重组修复途径 ...

自诞生以来，CRISPR-Cas9这把"基因魔剪"虽然掀起了生命科学研究的革命性浪潮。然而，面对那些"油盐不进"的难转染细胞，特别是原代免疫细胞，这把基因魔剪却常常无处施展。现在，这个难题终于迎来突破性解决方案！西湖凝聚体携手西湖大学研究团队重磅推出 ...

Gene-editing tools such as CRISPR/Cas9 can be used to create isogenic cell lines, which can be further used to model a specific patient population. An isogenic cell line was created to model ...

博生物自主开发的riboEDIT™ CRISPR-Cas9体系是采用天然复合物系统（crRNA和tracrRNA）进行基因编辑。 锐博提供基于Cas9 mRNA的全RNA体系和基于Cas9蛋白的RNP体系，tracrRNA可实现大规模合成，靶向DNA目的序列的crRNA可以高通量合成，针对哺乳动物细胞可简单通过化学转染或 ...

image: 报告RNA富集的双sgRNA核蛋白（reporter RNA enriched dual-sgRNA/CRISPR-Cas9 ribonucleoproteins, RE-DSRNP）高效编辑技术体系由双sgRNA编辑系统和报告RNA富集的核糖 ...

However, our understanding of how gradual changes in gene dosage affect molecular, cellular, and organismal traits is currently limited. To address this gap, we induced gradual changes in gene ...

YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for ATTR amyloidosis. The ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.